Pfizer (PFE) Non-Current Debt (2016 - 2025)
Historic Non-Current Debt for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $57.4 billion.
- Pfizer's Non-Current Debt fell 102.24% to $57.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $57.4 billion, marking a year-over-year decrease of 102.24%. This contributed to the annual value of $57.4 billion for FY2024, which is 741.13% down from last year.
- Pfizer's Non-Current Debt amounted to $57.4 billion in Q3 2025, which was down 102.24% from $57.5 billion recorded in Q2 2025.
- Over the past 5 years, Pfizer's Non-Current Debt peaked at $62.0 billion during Q4 2023, and registered a low of $31.7 billion during Q2 2023.
- Moreover, its 5-year median value for Non-Current Debt was $57.4 billion (2024), whereas its average is $47.5 billion.
- Per our database at Business Quant, Pfizer's Non-Current Debt plummeted by 3003.23% in 2021 and then surged by 9337.31% in 2024.
- Quarter analysis of 5 years shows Pfizer's Non-Current Debt stood at $36.2 billion in 2021, then fell by 8.83% to $33.0 billion in 2022, then surged by 87.88% to $62.0 billion in 2023, then dropped by 7.41% to $57.4 billion in 2024, then grew by 0.01% to $57.4 billion in 2025.
- Its Non-Current Debt stands at $57.4 billion for Q3 2025, versus $57.5 billion for Q2 2025 and $57.6 billion for Q1 2025.